产品
编 号：F525508
分子式：C9H8N2O
分子量：160.17
分子式：C9H8N2O
分子量：160.17
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
500mg
询价
询价
1g
询价
询价
结构图
CAS No: 93117-08-9
产品详情
生物活性：
5-AIQ (5-Aminoisoquinolin-1-one) is a water-soluble PARP-1 inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver.
体内研究：
5-AIQ (150 and 250 mg/kg; p.o.; once) possess no significantly genotoxic in vivo system by micronucleus test.5-AIQ (3 mg/kg; p.o.; 5 min prior to onset of liver ischemia) reduces the tissue injury associated with ischemia-reperfusion of the liver.Animal Model:Male mice
Dosage:150 and 250 mg/kg
Administration:Oral administration; 150 and 250 mg/kg; once
Result:Showed no increase of micronucleated polychromatic erythrocytes (MNPCE) in both 24 h and 48 h after both 125 and 250 mg/kg duration exposure as compared to the corresponding control.
Animal Model:Anesthetised male Wistar rats with liver ischemia (for 30 minutes) and reperfusion (for 2 hours)
Dosage:3 mg/kg
Administration:Intravenous injection; 3 mg/kg; 5 min prior to onset of liver ischemia
Result:Reduced PARP activation and showed less staining for ICAM-1.
体外研究：
5-AIQ (5000 μg) significantly reduces the number of colonies of TA 98 without metabolic activation, and TA 98 and TA 1537 with metabolic activation.
5-AIQ (5-Aminoisoquinolin-1-one) is a water-soluble PARP-1 inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver.
体内研究：
5-AIQ (150 and 250 mg/kg; p.o.; once) possess no significantly genotoxic in vivo system by micronucleus test.5-AIQ (3 mg/kg; p.o.; 5 min prior to onset of liver ischemia) reduces the tissue injury associated with ischemia-reperfusion of the liver.Animal Model:Male mice
Dosage:150 and 250 mg/kg
Administration:Oral administration; 150 and 250 mg/kg; once
Result:Showed no increase of micronucleated polychromatic erythrocytes (MNPCE) in both 24 h and 48 h after both 125 and 250 mg/kg duration exposure as compared to the corresponding control.
Animal Model:Anesthetised male Wistar rats with liver ischemia (for 30 minutes) and reperfusion (for 2 hours)
Dosage:3 mg/kg
Administration:Intravenous injection; 3 mg/kg; 5 min prior to onset of liver ischemia
Result:Reduced PARP activation and showed less staining for ICAM-1.
体外研究：
5-AIQ (5000 μg) significantly reduces the number of colonies of TA 98 without metabolic activation, and TA 98 and TA 1537 with metabolic activation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备